ESMO 2022 Conference Coverage
Playback speed
10 seconds
ESMO 2022 on Primary Endpoint Results of the Randomized Phase 2 SYNERGY Trial: 1L Chemo-IO of Durvalumab, Paclitaxel, and Carboplatin +/- Anti-CD73 Antibody Oleclumab in Advanced or Metastatic TNBC
By
ESMO 2022 Conference Coverage
FEATURING
Laurence Buisseret
By
ESMO 2022 Conference Coverage
FEATURING
Laurence Buisseret
82 views
September 27, 2022
Comments 0
Login to view comments.
Click here to Login
Breast